Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Bharathi Laxman; Scott A. Tomlins; Rohit Mehra; David S. Morris; Lei Wang; Beth E. Helgeson; Rajal B. Shah; Mark A. Rubin; John T. Wei; Arul M. Chinnaiyan

doi:10.1593/neo.06625

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Bharathi Laxman, Scott A. Tomlins, Rohit Mehra, David S. Morris, Lei Wang, Beth E. Helgeson, Rajal B. Shah, Mark A. Rubin, John T. Wei, Arul M. Chinnaiyan

Research output: Contribution to journal › Article › peer-review

206 Scopus citations

Abstract

We recently reported the identification of recurrent gene fusions in the majority of prostate cancers involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, and ETV4. Here we report the noninvasive detection of these gene fusions in the urine of patients with clinically localized prostate cancer. By quantitative polymerase chain reaction, we assessed the expression of ERG and TMPRSS2:ERG transcripts in urine samples obtained after prostatic massage from 19 patients (11 prebiopsy and 8 pre-radical prostatectomy) with prostate cancer. We observed a strong concordance between ERG overexpression and TMPRSS2:ERG expression, with 8 of 19 (42%) patients having detectable TMPRSS2:ERG transcripts in their urine. Importantly, by fluorescence in situ hybridization, we confirmed the presence or the absence of TMPRSS2:ERG gene fusions in matched prostate cancer tissue samples from three of three patients with fusion transcripts in their urine and from two of two patients without fusion transcripts in their urine. These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.

Original language	English (US)
Pages (from-to)	885-888
Number of pages	4
Journal	Neoplasia (New York, N.Y.)
Volume	8
Issue number	10
DOIs	https://doi.org/10.1593/neo.06625
State	Published - Oct 2006
Externally published	Yes

ASJC Scopus subject areas

Cancer Research

Access to Document

10.1593/neo.06625

Cite this

@article{ceb6401598d84129b3eda1ef21047039,

title = "Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.",

abstract = "We recently reported the identification of recurrent gene fusions in the majority of prostate cancers involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, and ETV4. Here we report the noninvasive detection of these gene fusions in the urine of patients with clinically localized prostate cancer. By quantitative polymerase chain reaction, we assessed the expression of ERG and TMPRSS2:ERG transcripts in urine samples obtained after prostatic massage from 19 patients (11 prebiopsy and 8 pre-radical prostatectomy) with prostate cancer. We observed a strong concordance between ERG overexpression and TMPRSS2:ERG expression, with 8 of 19 (42%) patients having detectable TMPRSS2:ERG transcripts in their urine. Importantly, by fluorescence in situ hybridization, we confirmed the presence or the absence of TMPRSS2:ERG gene fusions in matched prostate cancer tissue samples from three of three patients with fusion transcripts in their urine and from two of two patients without fusion transcripts in their urine. These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.",

author = "Bharathi Laxman and Tomlins, {Scott A.} and Rohit Mehra and Morris, {David S.} and Lei Wang and Helgeson, {Beth E.} and Shah, {Rajal B.} and Rubin, {Mark A.} and Wei, {John T.} and Chinnaiyan, {Arul M.}",

note = "Funding Information: Address all correspondence to: Arul M. Chinnaiyan, MD, PhD, Department of Pathology, University of Michigan Medical School, 1400 East Medical Center Drive 5316 CCGC, Ann Arbor, MI 48109-0602. E-mail: arul@umich.edu 1This work was supported, in part, by the National Institutes of Health Early Detection Research Network (UO1 CA111275-01 to A.M.C. and J.T.W.), the Prostate SPORE (P50CA69568 to K.JA.M.C. and R.B.S.), the Prostate Cancer Foundation (to A.M.C.), and the Department of Defense (PC040517 to R.M.). S.A.T. is supported by a Rackham Predoctoral Fellowship and is a fellow of the Medical Scientist Training Program. A.M.C. is supported by a Clinical Translational Research Award from the Burroughs Welcome Foundation. 2Co –first authors. Received 3 October 2006; Revised 3 October 2006; Accepted 3 October 2006.",

year = "2006",

month = oct,

doi = "10.1593/neo.06625",

language = "English (US)",

volume = "8",

pages = "885--888",

journal = "Neoplasia (New York, N.Y.)",

issn = "1522-8002",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

AU - Laxman, Bharathi

AU - Tomlins, Scott A.

AU - Mehra, Rohit

AU - Morris, David S.

AU - Wang, Lei

AU - Helgeson, Beth E.

AU - Shah, Rajal B.

AU - Rubin, Mark A.

AU - Wei, John T.

AU - Chinnaiyan, Arul M.

N1 - Funding Information: Address all correspondence to: Arul M. Chinnaiyan, MD, PhD, Department of Pathology, University of Michigan Medical School, 1400 East Medical Center Drive 5316 CCGC, Ann Arbor, MI 48109-0602. E-mail: arul@umich.edu 1This work was supported, in part, by the National Institutes of Health Early Detection Research Network (UO1 CA111275-01 to A.M.C. and J.T.W.), the Prostate SPORE (P50CA69568 to K.JA.M.C. and R.B.S.), the Prostate Cancer Foundation (to A.M.C.), and the Department of Defense (PC040517 to R.M.). S.A.T. is supported by a Rackham Predoctoral Fellowship and is a fellow of the Medical Scientist Training Program. A.M.C. is supported by a Clinical Translational Research Award from the Burroughs Welcome Foundation. 2Co –first authors. Received 3 October 2006; Revised 3 October 2006; Accepted 3 October 2006.

PY - 2006/10

Y1 - 2006/10

N2 - We recently reported the identification of recurrent gene fusions in the majority of prostate cancers involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, and ETV4. Here we report the noninvasive detection of these gene fusions in the urine of patients with clinically localized prostate cancer. By quantitative polymerase chain reaction, we assessed the expression of ERG and TMPRSS2:ERG transcripts in urine samples obtained after prostatic massage from 19 patients (11 prebiopsy and 8 pre-radical prostatectomy) with prostate cancer. We observed a strong concordance between ERG overexpression and TMPRSS2:ERG expression, with 8 of 19 (42%) patients having detectable TMPRSS2:ERG transcripts in their urine. Importantly, by fluorescence in situ hybridization, we confirmed the presence or the absence of TMPRSS2:ERG gene fusions in matched prostate cancer tissue samples from three of three patients with fusion transcripts in their urine and from two of two patients without fusion transcripts in their urine. These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.

AB - We recently reported the identification of recurrent gene fusions in the majority of prostate cancers involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, and ETV4. Here we report the noninvasive detection of these gene fusions in the urine of patients with clinically localized prostate cancer. By quantitative polymerase chain reaction, we assessed the expression of ERG and TMPRSS2:ERG transcripts in urine samples obtained after prostatic massage from 19 patients (11 prebiopsy and 8 pre-radical prostatectomy) with prostate cancer. We observed a strong concordance between ERG overexpression and TMPRSS2:ERG expression, with 8 of 19 (42%) patients having detectable TMPRSS2:ERG transcripts in their urine. Importantly, by fluorescence in situ hybridization, we confirmed the presence or the absence of TMPRSS2:ERG gene fusions in matched prostate cancer tissue samples from three of three patients with fusion transcripts in their urine and from two of two patients without fusion transcripts in their urine. These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33846785860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846785860&partnerID=8YFLogxK

U2 - 10.1593/neo.06625

DO - 10.1593/neo.06625

M3 - Article

C2 - 17059688

AN - SCOPUS:33846785860

SN - 1522-8002

VL - 8

SP - 885

EP - 888

JO - Neoplasia (New York, N.Y.)

JF - Neoplasia (New York, N.Y.)

IS - 10

ER -

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this